EFTA02180090

To: From: Sent Wed 11/9/2011 11:12:59 PM Subject Re: Ivory Coast CDC Health Information It looks pretty thorough to me! On Nov 9, 2011, at 6:11 PM,I wrote: I did. Do you think it's what he wants? I was a bit scared of him today !! Sent from my iPhone On Nov 9, 2011, at 5:43 PM, a wrote: thanks.. did you send this to JE as well? On Nov 9, 2011, at 3:21 PM, ivrote: e p a ri n g f r ri p t C 0 t e d' EF TA_R 1_00869348 EFTA02180090 Iv of r e B of or e vi si ti n 9 C at e di Iv of re y 0 ILI m ay n e e d to 9 et th e fo II 0 wi n 9 V3 CC in at lo n s a n d m e di ca EFTA_R1_00869349 EFTA02180091 ti n fo va cc in e- pr ev nt a bl di se as es a n d of h er di se as es 0 m ig ht b at ri sk fo at 0 Ur d es ti n at io n: N EFTA_R1_00869350 EFTA02180092 of Yo ur do Ct or or he alt h- ca re pr ov id er wi de to r mi ne w ha t y0 wi ne ed de pe nd in 9 on fa Ct or su Ch as yo ur he alt h an d im un EFTA_R1_00869351 EFTA02180093 iz ati on hi st Or Y. ar ea $ of th e co un tr y0 1/0 be vi sit in 9, an PI an ne 0 ac tiv iti es .) To ha ye th e m os t be ne fit se e he alt h- ca EFTA_R1_00869352 EFTA02180094 re pr ov id er at le as t 4- 6 w ee ks be fo re yo tar tn p to all 0 w ti m e fo r yo Ur va CCi ne s to ta ke of fe ct an 0 to st ar t ta ki ng m ed ici ne to pr EFTA_R1_00869353 EFTA02180095 ev en t m al art a, if yo ne ed it. Ev en if yo ha ve le ss th an 4 ve ee ks be fo re yo le av e, yo sh ou Id sb se e he alt h- ca re pr ov id er fo EFTA_R1_00869354 EFTA02180096 r ne ed ed va cci ne Si an ti- m al ari a dr ug $ an d ot he r m ed is ati on $ an a inf or m ati on ab ou ho w to pr ot ec yo ur se If fr O m it ne ss an d EFTA_R1_00869355 EFTA02180097 inj ur w hil e tr av eli ng C D C re co m m en ds th at yo se e he alt h- ca re pr ov id er w ho sp ec ial iz es in Tr av el M ed ici ne Li EEL B_ tE EFTA_R1_008693543 EFTA02180098 m 1i ne ni c ne ar yo u. If yo ha ye a m ed is al co nd iti on yo sh ou Id al so sh ar e yo ur tr av el pl an wi th an y do a or yo ar EFTA_R1_00869357 EFTA02180099 e cu rr en tly se ei ng fo r of he r ed ic al re as on s. If yo ur tr av el PI an wi I to ke yo to or e th an on e co un tr du ri ng a si ng le tri EFTA_R1_00869358 EFTA02180100 p. be su re to let y0 ur he alt h- Ca re pr ov id er kn O w so th at yo ca n re ce iv e th e ap pr op ria to va cci na do ns an d inf or m ati on fo r all of yo ur de EFTA_R1_00869359 EFTA02180101 sti na do ns LO 119- te r m tr av el er s, su ch as th os e w ho pl an to w Or k or st ud y ab r0 ad m ay al so ne ed ad dit io na va cci na do ns as re qu ire EFTA_R1_00869360 EFTA02180102 d by th eir e m pi oy er Or Sc ho ol. B e $ ur y 0 ur ro ut in va cc in at io n ar p- to- d at e. C h ec k th i n ks b el 0 w to se EFTA_R1_00869361 EFTA02180103 w hi ch va cc in at io n s a d Ili is a n d ch Il dr e n s h 0 ul d 9 et R 0 ut in e va cc in es as th ey ar e of to n Ca Ile 0, su ch as fo r EFTA_R1_00869362 EFTA02180104 inf lu en 2,3 Ch ic ke np ox (o r va nc ell a) po lio m ea sl es m m ps /r ub ell a (hi M R) an d di ph th en a/ pe rt us sis /t et an us (D PT ar e EFTA_R1_00869363 EFTA02180105 gi ve n at all st ag es of hf e; se e th e Sh fig ha SOL St ag ce 1PLI MO iz cat 411 14 an d rs liti mit im ID sin iz asi he sist le• RO uti ne EFTA_R1_00869364 EFTA02180106 va cci ne ar e re co in in en de d ev en if yo do no t tr av el. Al th ou gh Ch ild ho od di se as es su Ch as ea sl es ra rel oc cu r in th e nit ed EFTA_R1_00869365 EFTA02180107 St at es th ey ar e sti I co m m on in m an pa rt of th e w orl d. tr av el er w ho is no va cci na to d w ou Id be at ris k fo r inf ec tio n. V EFTA_R1_00869366 EFTA02180108 rr a- M 0 CL fD fa/ 0' fD aim 3 3 2, mz < LA (I) Lei CLI rD iron OCD cr rt.= (1) < N -% -O? z n n m Ix 0 8 EFTA02180109 EFTA02180110 co 8 0 0 w > to .3 4) -ti -I% .t 2 E coca al 4.1 c ar5 -Ewa) > "6 t ° > 'vc iv' w >ivt'm n.5ducutmc arcl w rn w.a a n y tl m e. Recommendations or Vaccination or Requirements for Vaccine- Disease Preventable Diseases ROutme Recommended if you are not up-to-date with routine shots, such as measles/mumps/rubella (MMR) vaccine, diphtheria/pertussis/tetanus (OPT) vaccine, poliovirus vaccine, etc. Hepatitis A or Recommended for all unvaccinated immune people traveling to or working in globulin (IG) countries with an intermediate or high level of hepatitis A virus infection (at mao) where exposure might occur through food or water. Cases of travel- : related hepatitis A can also occur in travelers to developing countries with "standard" tourist itineraries, accommodations, and food consumption behaviors. Hepatitis B Recommended for all unvaccinated persons traveling to or working in countries with intermediate to high levels of endemic HBV transmission (see map, especially those who might be exposed to blood or body fluids, have sexual contact with the local population, or be exposed through medical treatment (e.g., for an accident). Tvohoig Recommended for all unvaccinated people traveling to or working in West Africa, especially if staying with friends or relatives or visiting smaller cities, villages, or rural areas where exposure might occur through food or water. POO Recommended for adult travelers who have received a primary series with either inactivated poliovirus vaccine (IPV) or oral polio vaccine (OPV). They should receive another dose of IPV before departure. For adults, available data do not indicate the need for more than a single lifetime booster dose with WV. EFTA_R1_00869389 EFTA02180111 Yellow Fever Requirements: Required upon arrival from all countries for travelers 21 year of age. Recommendations: Recommended fo r all travelers 29 months of age. Vaccination should be given 10 days before travel and at 10-year intervals if there is on-going risk. Find an authorized U.S. yellow fever vaccination clinic. Meninaococcal Recommended If you plan to visit (meningitis) countries that experience epidemics of meningococcal disease during December through June (see map). Rabies Recommended for travelers spending a lot of time outdoors, especially in rural areas, involved in activities such as bicycling, camping, or hiking. Also recommended for travelers with significant occupational risks (such as veterinarians), for long-term travelers and expatriates living in areas with a significant risk of exposure, and for travelers involved in any activities that might bring them into direct contact with bats, carnivores, and other mammals. Children are considered at higher risk because they tend to play with animals, may receive more severe bites, or may not report bites. M at a ri a EFTA_R1_00869370 EFTA02180112 EFTA_R1_00869371 EFTA02180113 Ir iy 0 iv ti tg ly 0 In CI uc: e th fol lo ng EFTA_R1_00869372 EFTA02180114 EFTA_R1_00869373 EFTA02180115 EFTA_R1_00869374 EFTA02180116 EFTA_R1_00869375 EFTA02180117 9 eq op 10 fls 0 pr ev en in 1,1 al ar a Co to vo ire A to qu on pr 09 lid ml do xy cy Cli ne or m efI oq LJI ne or de tal EFTA_R1_00869376 EFTA02180118 EFTA_R1_00869377 EFTA02180119 e 0 it to t Ir le le if h 9 Id be be St fo r yo u. Pt ea se se EFTA_R1_ 00869378 EFTA02180120 N of C hl or 0 ui n is N O T a n of fe Ct iv a nt m al ar is d 9 in C of Iv re a n d h 0 ul of b k EFTA_R1_ 00869379 EFTA02180121 to pr cv nt m al ar is in th is re O In n ah On tl 1'0 ug ho ut th yo us Ill EFTA_R1_00869380 EFTA02180122 EFTA_R1_00869381 EFTA02180123 ati on an d th e re co m m en de d Pr ev en to m ed ici ne $ fo r th at ar ea al ar is C 0 nt ac t to H e al th- C ar Pr 0 vi d er For assistance with the diagnosis or management of SU EFTA_R1_00869382 EFTA02180124 sp ec to ca se of m al ari a, ca I th e C D C M al an a H otl in e: 77 0- 48 8- 77 88 (M- F, 9 a m- 5 p m Ea st er n ti m e) FO r e m er ge nc EFTA_R1_00869383 EFTA02180125 co ns ult ati on of to r ho ur s, ca 77 0- 48 8- 71 00 an as k to sp ea k wi th a C D C al ari a Br an Ch Cli ni Ci an A S p ec is N of e EFTA_R1_00869384 EFTA02180126 b 0 ut A nt m al ar is Dr gs YID sh ou Id pu rC ha se yo ur an ti m al ari at dr ug $ be fo re tr av el. Dr ug $ pu rC ha se d ov er se as m ay no t EFTA_R1_00869385 EFTA02180127 be m an of ac to re d ac co rd in 9 to nit ed St at es st an da rd an ay no be of fe cti ye Th ey al so ay be da ng er ou s, co nt ai n co un to rf EFTA_R1_00869386 EFTA02180128 eit m ed ic ati on or co nt a mi na nt s, or be co m bi na do ns of or ug th at ar e no t sa fe to us e. H al of an tri ne m ar ke to as H alf an is EFTA_R1_00869387 EFTA02180129 wi de ly us ed ov er se as to tr ea t m al ari a. C D C re co m m en ds th at y0 do N T us e ha lof an tri ne be ca us e of se rio us he ar t- rel at ed si de EFTA_R1_00869388 EFTA02180130 of fe Ct s, in CI ud in de at hs Yo sh ou Id av Oi d us in an ti m al an al dr ug $ th at ar e no t re co m m en de d nl es yo ha ye be en di EFTA_R1_00869389 EFTA02180131 ag no se d wi th lif e- th re at en in 9 m al ari a an no of he r op tio ns 3r e im m ed iat el V av ail ab le. FO r de tai le int or m ati on ab ou th es e EFTA_R1_00869390 EFTA02180132 an tl al an al 0r ug s, se a bs in Mt le_ gn ari a• M r e In fo r m at io n b 0 t M al a ri a 14 al ar EFTA_R1_00869391 EFTA02180133 la is al w ay s a se rio us di se as e an d m ay be a de ad ly ill ne ss H u m an s ge t rn al ari a fr 0 m th e bit e of a m os qu ito inf ec to d wi th EFTA_R1_00869392 EFTA02180134 th e pa ra sit e. Pr ev en t thi se rio us di se as e by se ei ng yo ur he alt h- Ca re pr ov id er fo r pr es cri pti on an ti al an al dr ug an d by pr of ec tin EFTA_R1_00869393 EFTA02180135 g yo ur se If ag ai ns m os qu ito bit es ee, kg LIO Tr av el er $ to al an ris k- ar ea $ in C6 to vo ire in CI ucl in 9 inf an ts, ch ilo re n, an EFTA_R1_00869394 EFTA02180136 fo r m er re si de nt of Co te vo ire sh ou Id to Ice on e of th e an ti m al ari al Or ug lis te 0 in th e bo x ab ov e. $ m t 0 m 5 EFTA_R1_00869395 EFTA02180137 M al an a sy m Pt 0 m s m ay in CI ud e • f e v e r • c h i 1 I s • s w e a t s • h e a d a c h e • b 0 d y a c EFTA_R1_00869396 EFTA02180138 h e s • n a u s e a a n d v 0 m i t i n 9 • f a t I 9 u e M at ari a sy m pt 0 m s wi II of Cu r at le as t 7 to 9 da ys of to EFTA_R1_00869397 EFTA02180139 r be in 9 bit te n by an Inf ec te m os qu ito Fe ye r in th e fir st w ee k of tr av el in a m al ari a- ris k ar ea is un lik el y to be m al ari a; ho w ev EFTA_R1_00869398 EFTA02180140 er yo sh ou Id se e do ct or ri gh t w ay if yo de ye lo a fe ye r Cu ri ng yo ur tri p. M al an m ay Ca US e an e mi a an C ja un Ci ce EFTA_R1_00869399 EFTA02180141 M al an a inf ec do ns WI th PI as fil od iu fa/ ci pa ru if no t pr a m ptl tr ea to d, m ay ca us e ki do ey fai lu re co a, an d de at h. D es EFTA_R1_00869400 EFTA02180142 pit e us in 9 th e pr of ec tiv e ea su re $ ou to ne ab ov e, tr av el er m ay sti de ye lo p m al ari a up to a ye ar of to r re to rn in 9 fr 0 m EFTA_R1_00869401 EFTA02180143 a al all Cu $ ar ea Yo sh ou Id se e do ct or um m ed lat el y if yo de ye to a fe ye r an yti e du ri ng th e ye ar fol lo WI ng yo ur re to rn EFTA_R1_00869402 EFTA02180144 an tel th e ph y5 id an of yo ur tr av el. It e m t O B ri it h O e di ci n 0 m ay n e e d: T h EFTA_R1_00869403 EFTA02180145 cc 0 Dm fr, < cu 7 c O.< cli -t c in i'D r tux • .< iv a< n8COMM CS "C 0 •C a ID 3 'el 'CL al 3 3 0 0,13 --1 n b tint al lO 0 2 0 EFTA02180146 a h t 0 t d r 9 0 r r K e e t h e n t h e r 0 r n r e r t 0 n b 0 EFTA_R1_00869405 EFTA02180147 0.0 •-‹ •-•• — •-• c 0 et sn * O -- 0 - I• 0^ et -3 c 00 03 • MC CY 0 IC) C - 3 01 -1 -1 CV O -I c 0 ••< z — III ••< te * — ft Cc 3 CV V/ Ci — EFTA02180148 u i d e i n e s < i c 0 n 0 u t P n 9 > i f t h e m e d i c i n e s a r e i cl u i d $ • A n t i m a I a EFTA_R1_00869407 EFTA02180149 r i a I d r u 9 s i f t r a v e i n 9 t 0 a m a a r i a- r i s k a r e a i n C 8 t e d I v 0 i r e a n d P EFTA_R1_00869408 EFTA02180150 r e $ r b e d b 0 r d 0 t 0 r • M e d n e f 0 r d r r h e a 0 V e - t h - EFTA_R1_00869409 EFTA02180151 C 0 U n t e r N ot e: So m e Er ug $ av ail ab le by pr es cri pti on in th e U S ar e it eg al in ot he r co un tri es C he ck th e U S D ep ar EFTA_R1_00869410 EFTA02180152 m en of St at e cQ of 19 ID he gt <i co n_ ou t. pn 9 fo r th e co un tr s) yo int en d to vi sit or th e e m ba ss or CO EFTA_R1_00869411 EFTA02180153 ns ul at e fo r th at co un tr Y( 5) If yo Ur m ad is ati on is no t all 0 w ed in th e co un tr yo U wi be vi sit in 9, as k yo Ur he alt h- ca re pr oy id EFTA_R1_00869412 EFTA02180154 er to wr ite a let to r on of fiC e st ati on er st ati ng th e m ed ic ati on ha be en pr es Crl be d fo r yo u. Ot h er it m y 0 in ay n d: EFTA_R1_00869413 EFTA02180155 N et r• O a CP O n "s (T) " CV CD " ", 0 -0 aD as wet ID — awry ID 7 a 0 •-• • m ID i0 EFTA02180156 d w t e r $ n 0 t V a e e e e t w t e r F t e r e t 0 C 0 m m EFTA_R1_00869415 EFTA02180157 e r C a I I Y- B 0 t t e d W a t e r a n d O t h e r B e v e r a 9 e s a n d S a f e F 0 o d a n d W a t e r EFTA_R1_00869416 EFTA02180158 f 0 r m 0 r e d e t a i I e d i n f 0 r m a t i 0 n • S u n b 0 c k a n d s u n 9 a s s e s f 0 r P r 0 t e c EFTA_R1_00869417 EFTA02180159 O r O m r m f U e e t O U S U r S e e B I n 0 r m 0 n b 0 U t EFTA_R1_00869418 EFTA02180160 S k n C a n c e r f 0 r m 0 r e n f 0 r m a t 0 n A n t b a c t e r a I h a n d w P e s 0 r a c EFTA_R1_00869419 EFTA02180161 0 h 0 a e d h d t z e r 0 n t 9 t e t 0 0/0 a 0 h 0 • To prevent Insect/mosquito bites, bring: o Lightweight long-sleeved shirts, long pants, and a hat to wear outside, whenever possible. o Flying-Insect spray to help dear rooms of mosquitoes. The product should contain a pyrethrold insecticide; these Insecticides quickly kill flying Insects, Including mosquitoes. o Bed nets treated with permethrin, if you will not be sleeping In an air-conditioned or well-screened EFTA_R1_00869420 EFTA02180162 room and will be in malaria-risk areas. For use and purchasing information, seelnsecticide Treated Bed Nets on the CDC malaria site. Overseas, permethrin or another insecticide, deltamethrin, may be purchased to treat bed nets and clothes. Se e ot he r su 99 es te d ov er- th e- co un te r m ed lc at, on an d fir st al d Ite m fo r tr av el er s' he alt h N ot e: C he EFTA_R1_00869421 EFTA02180163 Ck th e Al r Tr 41. en <I CO n_ Cu t. pn 9 > of th e an SR 9.r tie n_ Si Cu Lit y_ A mi Dl It La tie <i co n_ ou t. pn 9 w eb sit e fo r th e EFTA_R1_00869422 EFTA02180164 lat es t inf or m ati on ab ou t air po rt sc re en in 9 pr oc ed ur es an pr oh ibi to ite m s. To nf Pd 0 t h e r D is e e F EFTA_R 1_00869423 EFTA02180165 O u n d in W e st A fr is a Risk can vary between countries within this region and at so wi th in a CO u nt ry th e cl ua lit y of in- co u nt ry su ry ei El an ce at so va ri es Th e fol lo vo ng EFTA_R1_00869424 EFTA02180166 ar e di se as e ris k$ th at mi gh of fe ct tr av el er s; thi $ is no a co m PI et e lis of di se as es th at ca n be pr es en t. En vir on m en tal co nd iti EFTA_R1_00869425 EFTA02180167 on m ay al so Ch an ge an up to da to inf or m as on ab ou t ris k by re 91 on wi thi a co un tr y m ay al so no t al w ay $ be av ail ab le. D en EFTA_R1_00869426 EFTA02180168 2, fll is li m an Qn Qc ci is (ri ye r bli nO ne ss ar e of he r di se as es ca rri eci by in se ct th at al so oc Cu r in EFTA_R1_00869427 EFTA02180169 es t At Ht a. A Id CA Y.32 Ali IL L fri Di act. ic kL 4,4 sl h as in Cr ea se d in Af ric a (it is ep id e mi in A ng of a, D e m oc ra EFTA_R1_00869428 EFTA02180170 tic Re pu bli C of th e Co ng o, an th e $ ucl an • an hi gh ly en de mi C in Ca m er 00 n, Ce In ral Af ric an Re pu bli C, C ha Co ng o, C8 to crl vo ire G EFTA_R1_00869429 EFTA02180171 ui ne a, oz a bi qu e, ga nd a, an d Ta nz an is io w le ve Is ar e fo un d in m os t of th e of he co un to es ), an d an in Cr ea se in tr av el EFTA_R1_00869430 EFTA02180172 er ha be en no to d si nc e 20 00 os t ha d ex po su re in ia nz an a an d Ke ny a, re fle cti ng co m m on to ur ist ro ut es IF,t6PgRaP' EFTA_R1_00869431 EFTA02180173 a If n.s in SL 1t w it he 1p to Pr ev en th es e di se as es SS hi SS 9$ ml is, a pa ra sit is inf ec tio n, ca be co rit ra ct ed in fr es EFTA_R1_00869432 EFTA02180174 h w at er in thi re 91 on D 0 no t $ wi m in fr es h w at er (e xc ep t in w ell- ch lor in at ed $ wi m mi ng po 01 s) in th es e co un to es P9 EFTA_R1_00869433 EFTA02180175 ho 0 ut br ea ks yr er e re po rt ed in se ve ral pr ev io us ly po lio- fr ee Co un trt es in Ce nt ral Ea st er n, an d es to rn Af riC be gi nn in 9 in 20 03 EFTA_R1_00869434 EFTA02180176 Po lio is sti II en de mi c in Ni ge ria Tr av el er s to ru ral ar ea s of w es t Af riC a m ay be ex po se d to I. Li sa Yir sil w hi ch is sp re ad th IV ug EFTA_R1_00869435 EFTA02180177 h co nt ac wi th ra ur in e or Cr op pi ng s. Pe op le ca n be ex po se to La ss a vir us by in ha lin 9 tin y pa rti CI es of th es e ex Cr etl on in th e EFTA_R1_00869436 EFTA02180178 air es pe ci all if th ey st ay in tr ad iti on al w ell in gs Tr av el er sh Cu Id av of co nt ac wi th ra is an d sh ou Id no st ay in d w ell in EFTA_R1_00869437 EFTA02180179 gs th at m ay be inf es to d vn th To ts. H m an- to- hu an tr an mi ssi on of th e di se as e ha be en de Sc ri be d. 12 R5 L EA 17_ Pr ALI DA $ EFTA_R1_00869438 EFTA02180180 ho ul d be fol lo ed to pr ev en t hu m an- to- hu m an tr an mi ssi on fr O m inf ec to d pe op le. Hi gh ly pa th og en is av is n inf lu en za (H S N 1) ha EFTA_R1_00869439 EFTA02180181 be en fo un d in po ult ry po pu lat io ns in se ye ral to un to es in Af riC a. Av di d all di re a co nt ac t wi th bi rd s, in Cl u0 in 9 do m es tic po ult ry (a uc EFTA_R1_00869440 EFTA02180182 h as ch IC Ice ns an a du ck s) an wi Id bi rd s, an av oi pi aC es su ch as p0 ult ry fa r an a bi rd m ar ke is w he re liv e bi rd 5 ar e rai se EFTA_R1_00869441 EFTA02180183 or ke Pt FO r Cu rr en 'Is of co un to es re po rti ng ou tb re ak of H N a m on 9 po ult ry an or vn Id bi rd 5, vi e w YR 9s1 If 52 Q EFTA_R1_00869442 EFTA02180184 In I gti Qr gd Di is fq L Di ea H DL) (Q ic on O ut .p ng >, an d fo r to tal nu m be rs of co nfi r m ed hu an ca se $ of H N EFTA_R1_00869443 EFTA02180185 Vir US by co un tr se e th e 361 .11 Sta Ian 0 w QL AY ia 0 an Sit CO n_ ou t. On 9 M an y co un tri es in thi $ EFTA_R1_00869444 EFTA02180186 re 9' on ha ye hi gh in ci de nc e ra te $ of ILO sis a nd hi gh H TV re va le nc e ra te s. To of pa ge t yl n H e al t EFTA_R1_00869445 EFTA02180187 (0 CA a.< in (i) < -o 7 E. a IS'. • is' to rD - ro r, co n n N in 5 rt -o 7 -I 7 c 0 - On 7C 0`.< EFTA02180188 ng ar e sp re ad th r0 ug in se ct bit es 0 ne of th e be st pr of ec do ns is to pr ev en t in se ct bit es by • U 9 e t r EFTA_R1_00869447 EFTA02180189 e e e t C b r t h 0 %- 5 0 D E E C r V a b e a EFTA_R1_00869448 EFTA02180190 1 5 % C o n c e n t r a t i 0 n s n e e d s m 0 r e f r e cl u e n t a P P i c a t 0 n T h e r e i s I e s s EFTA_R1_00869449 EFTA02180191 n O r m t 0 n V a b e 0 n h O e e t V e r n t r 0 t e t n a 9 EFTA_R1_00869450 EFTA02180192 n $ t 0 t h e t e 0 m 0 t 0 e t h t t r n $ t m a r • e a r n 9 EFTA_R1_00869451 EFTA02180193 0 n 9- s e e v e d s h i r t s I 0 n 9 P a n t s a n d a h a t 0 u t d 0 0 r s • R e m a i n i n 9 i n d 0 0 EFTA_R1_00869452 EFTA02180194 r e e e d 0 r r- 0 t 0 e d e d r 9 t h e e 14 n 9 e r d f EFTA_R1_00869453 EFTA02180195 0 r in a a r i a ( d u s k a n d d a w n ) • S I e e P i n 9 i n b e d s c 0 v e r e d b Y n e t s t r e a t e d EFTA_R1_00869454 EFTA02180196 vi I t Ii P e r m e t h r i ri i f n 0 t s e e P I n 9 i n a n a i r- c 0 n d i t i 0 n e d 0 r w e I- s C r e e n e EFTA_R1_00869455 EFTA02180197 d r 0 0 m • S P r a Y i n 9 r 0 0 m s w i t h P r 0 d u c t s e f f e c t i v e a 9 a i n s t f Y i n 9 i n s e EFTA_R1_00869456 EFTA02180198 C t U C h $ t h 0 e C 0 t 9 p r e t h r 0 Fo r de tai le d mf or m ati on ab ou t in se Ct re pe Ile nt EFTA_R1_00869457 EFTA02180199 IS 1° SP PignaWlaS la UR: P P r e v e n t A ni m al Bi t e s a n d S c r a t c h e s Di re ct EFTA_R1_00869458 EFTA02180200 co nt ac t wi th an im al Ca sp re ad di se as es lik e ra bi es or ca us e se no us inj jr or it ne ss It is im po rt an t to pr ev en t an im al bit es an EFTA_R1_00869459 EFTA02180201 ^ODOC)• • DO '^dD - nnoi<wc mak " CD ^ ^N O. 0 el' C C• C O•< C tn N co • m I x i o 0 EFTA02180202 0 t 0 It 0 r e e n n m n n 9 0 9 $ n t E V e n n m t t EFTA_R1_00869461 EFTA02180203 0 0 k k e h e t h e t h V e r e 0 t h e d e e H e d EFTA_R1_00869462 EFTA02180204 e n s t a Y s a f e b Y s u P e r v i s i n 9 t h e m c a r e f u I Y a r 0 u n d a I a n i m a I s • I f Y 0 EFTA_R1_00869463 EFTA02180205 u a r e b t t e n 0 r s c r a t c h e d w a s h t h e w 0 u n d w e I w i t h s 0 a P a n d w a t e r a n d 9 EFTA_R1_00869464 EFTA02180206 0 t 0 a d 0 c t 0 r r i 9 h t a w a Y A f t e r Y 0 u r t r P b e s u r e t 0 t e I Y 0 u r d 0 c t 0 r EFTA_R1_00869465 EFTA02180207 0 r s t a t e h e a t h d e P a r t m e n t i f Y 0 u w e r e b i t t e n 0 r s c r a t c h e d d u r i n 9 t r a v EFTA_R1_00869466 EFTA02180208 e Fo r n or e inf or n ati on ab ou t ra bu es an d tr av el, se e m e血브亞m明뾰r中아m e血 血 且 曲 姚 0 rC巾Qq立血벼至mmm四 EFTA Ri 00869467 EFTA02180209 e. Fo r or e inf or au on ab ou ho w to pr of ec yo ur se If fr 0 of he r ris ks rel at ed to an im al 5, se eA Di m ak ci at ESL Iz at EFTA_R1_00869468 EFTA02180210 N gt, to 5 ,°1 ri m 0 s,' m ,c4 F a ca' a 3' 3 0 t &I', ,tg 9 rD rr w Eam d ao o m e't C 0 0- ro n co co m ID 0 8 EFTA02180211 of II ne ss in tr av el er s. Fo lb w th es e tip $ fo r sa fe ea tin 9 an Cr in ki ng a h Il r h n 0 t e n w t h EFTA_R1_00869470 EFTA02180212 0 a P a n d w a t e r e s P e c i a I I Y b e f 0 r e e a t i n 9 I f s 0 a P a n d w a t e r a r e n 0 t a v a EFTA_R1_00869471 EFTA02180213 i a b e u s e a n a c 0 h 0 b a s e d h a n d 9 e ( IN i t h a t e a s t 6 0 % a c 0 h 0 ) • D r EFTA_R1_00869472 EFTA02180214 M CU n M VI rn O. — ao C 17" O.M " CU MO an a fl -I fp er pi a (1) -.0 a -% aft — re. no a —Dor m Ix 0 EFTA02180215 W S 0 r b 0 t t e s A v 0 i d t a P w a t e r f 0 u n t a i n d r i n k s a n d i C e c u b e s I f t h EFTA_R1_00869474 EFTA02180216 n t 0 $ e e r n h 0 w t 0 m k e w t e r $ e r t d rl k D 0 0 t e EFTA_R1_00869475 EFTA02180217 0 0 d P u r c h a s e d f r 0 m s t r e e t v e n d 0 r s • M a k e s u r e f 0 0 d I s f u I Y c 0 0 k e d EFTA_R1_00869476 EFTA02180218 A v 0 i d d a i r Y P r 0 d u c t s u n I e s s Y 0 u k n 0 w t h e Y h a v e b e e n P a s t e u r i z e d Di EFTA_R1_00869477 EFTA02180219 se as es fr O fo od an d yr at er of to n ca us e vo mi tin 9 an d di ar rh ea ak e su re to br in 9 di ar rh ea m ed ici ne wi th yo so th at yo Ca EFTA_R1_00869478 EFTA02180220 tr ea t ml Id ca se $ yo Ur se If. A V of d In ri e Ca r cr as he ar e le ad in 9 ca us e of in a m on 9 tr av el er s. Pr EFTA_R1_00869479 EFTA02180221 of ec yo ur se If fr 0 m th es e inj ur ie $ by N t d r n k n n d r V n e r n 9 y 0 r EFTA_R1_00869480 EFTA02180222 e a t b e t a n d u s i n 9 c a r s e a t s 0 r b 0 0 s t e r s e a t s n t h e b a c k s e a t f 0 r c h i I d r EFTA_R1_00869481 EFTA02180223 e n • F 0 0 n 0 t r a w $ e a r n 9 e m e t w h e n 0 r e b EFTA_R1_00869482 EFTA02180224 I k e s m 0 t 0 r c Y c e s a n d m 0 t 0 r b i k e s • N 0 t 9 e t t i n 9 0 n a n 0 v e r 0 a d e d b u EFTA_R1_00869483 EFTA02180225 S O r n b S • H r n 0 d V e r w h e n O S $ e A V 0 n 9 n 9 h EFTA_R1_00869484 EFTA02180226 t d r i v i n 9 0 t h e r H e al t h Ti P s • T 0 a v 0 i d i n f e c t i 0 n s s u c h a s H I V a n EFTA_R1_00869485 EFTA02180227 000nryal^n0 - .01 CD - 0.000MM - ‘0)7M POMOO.M — ^ — nCil'OM= — Ci.0 4" — <0. m ID O 8 EFTA02180228 n e t 0 n • T 0 r e d e t h e r k 0 H I a n d 0 t h e r e x t r n t t e d EFTA_R1_00869487 EFTA02180229 d i s e a s e s a vi a Y s u s e a t e x c 0 n d 0 m s • T 0 P r e v e n t f u n 9 a a n d P a r a s i t i C EFTA_R1_00869488 EFTA02180230 n f e c t i 0 n s , k e e P f e e t c e a n a n d d r Y a n d d 0 n 0 t 9 0 b a r e f 0 0 t e s P e c i a EFTA_R1_00869489 EFTA02180231 0 n b e h e w h e r e n m m h V e d e f e e of Pa ge A ft e O R e EFTA_R1_00869490 EFTA02180232 t u r n H O m e If yo u ar e no t fe eli ng w eli yo u sh ou Id se e yo ur do ct or an d m en tio n th at yo u ha ye re ce ntl y tr av el ed EFTA_R1_00869491 EFTA02180233 Al so tel yo ur do ct or If y0 er e but to or sc ra tc he d by an an urn al w hi' e tr av eli ng If yo ha ye vi sit ed a al an a- ris k ar ea co EFTA_R1_00869492 EFTA02180234 nu nu e to ki ng yo ur an ti m al ari al dr ug fo r w ee k$ (cl ox yc yc lin e or m en oq ui ne or se ye n da ys (a to va qu on e/ pr og ua nil of to r le av EFTA_R1_00869493 EFTA02180235 in 9 th e riS k ar ea 14 ar is is w ay a se ri 0 di se as a n d m ay b d di y it n es s. If yo be co m e it wi th a EFTA_R1_00869494 EFTA02180236 fe ye or flu- lik e it ne ss elt he w hil e tr av ell ng in a m al ari a- ris k ar ea or of to yo re to rn ho m e (f or up to 1 ye ar ), yo sh ou Id se ek EFTA_R1_00869495 EFTA02180237 m m di at ed IC al at to nti on an d sh ou Id tel th e ph ys ICI an yo ur tr av el hi st Or iP it N dl u EFTA_R1_00Et69496 EFTA02180238 Is In EFTA_R1_00869497 EFTA02180239 at io n re' la to d Y 0 ur n io n er, fo' r pr nt w 0 EFTA_R1_00889498 EFTA02180240 To 2 of Pa ta M a P DI Sc Ia I m EFTA_R1_00Et69499 EFTA02180241 er Th e bo un da rie $ an na es sh 0 w n an th e de si gn ati on us ed on m ap do no t im pl th ex pr es Si on of an op ini on w ha is oe EFTA_R1_00869500 EFTA02180242 ve r on th e pa rt of th e Ce nt er fo r Di se as Co nt rol an d Pr eV en do n co nc er ni ng th e It ga st at us of an co un tr Y. to rri to FY Cit EFTA_R1_00869501 EFTA02180243 or ar ea or of its au th on tie s, or co nc er ni ng th de li mi to do of its fr on tie rs or bo un da rie s. A pp ro xi m at bo rd er lin es fo r w hi Cl, th er e EFTA_R1_00869502 EFTA02180244 ay no t ye t be fu! .39 re e m en t ar e ge ne ral ly ar ke d. Text size: M XL Email page Print page Bookmark and share Add this to... Favorites Deticio.L45 Digg Facebook Google Bookmarks Yahoo MyWeb Get email updates Contact Us: Centers for Disease Control and Prevention 1600 Clifton Rd Atlanta, GA 30333 800-CDC-INFO (900-232.4636) TTY: (888) 232-6348 New Hours of Operation 8am-8pm ET/Monday-Friday Closed Holidays g_d_chtfolvspc.gcw Email page Print page Bookmark and share EFTA_R1_00869503 EFTA02180245 Add this to... Favorites Digg Facebook Google Bookmarks Yahoo MyWeb Get email updates Page created: February 22, 2011 Page last updated: November 03, 2011 Page last reviewed: September 29, 2011 Content source: Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases (NCEZIO) Division of Global Migration and Quarantine (DGMQ) Travelers' HealthAll CDC Topics Search The CDC Search Button On Nov 9, 2011, at 2:53 PM, Jeffrey Epstein wrote: find out about disease shots for ivory coast. rasseck tells me malaria is there ** The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return c-mail or by e-mail to kevacationftamail com, and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA_R1_00869504 EFTA02180246